Oncolytics Biotech Reports Updated Randomized Phase 2 Data From BRACELET-1 Metastatic Breast Cancer Trial
Portfolio Pulse from Benzinga Newsdesk
Oncolytics Biotech reported updated Phase 2 data from its BRACELET-1 metastatic breast cancer trial, showing a 71% reduction in disease progression risk and a 37.5% overall response rate with the pelareorep-paclitaxel combination compared to 13.3% with paclitaxel monotherapy.
June 05, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncolytics Biotech's updated Phase 2 data from BRACELET-1 trial shows promising results for pelareorep-paclitaxel combination in metastatic breast cancer treatment.
The updated Phase 2 data from Oncolytics Biotech's BRACELET-1 trial shows a significant reduction in disease progression risk and an increased overall response rate with the pelareorep-paclitaxel combination compared to paclitaxel monotherapy. This positive news is likely to have a positive impact on the company's stock price in the short term, as it demonstrates the potential effectiveness of their treatment for metastatic breast cancer.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100